References
Patent
- Incept LLC. US8,044,137 (2011).
Websites
- Abbott to separate into two leading companies in diversified medical products and research-based pharmaceuticals. www.abbott.com/news-media/press-releases/2011-oct19-2.htm (Accessed 23November2011)
- Abbott to split into two companies, shares rise. Article on Reuters website by Ransdell Pierson and Lewis Krauskopf with additional material from Ben Hirschler. The article was edited by Dave Zimmerman and Maureen Bavdek. www.reuters.com/article/2011/10/19/us-abbott-idUSTRE79I46K20111019 (Accessed 23November2011)
- Arrowhead Research Corporation acquires Roche RNA assets and site. http://www.arrowres.com/publications/october24_2011.html (Accessed 23November2011)
- White Paper on Arrowhead Corporation website on Dynamic PolyConjugate™ technology. www.arrowheadresearch.com/pdf/Arrowhead-Research-Corporation_-_DPC-Technology-White-Paper-November2011.pdf (Accessed 23November2011)
- SurModics announces agreement to sell pharmaceutical assets. http://phx.corporate-ir.net/phoenix.zhtml?c=80353&p=irol-newsArticle&ID=1624681&highlight= (Accessed 23November2011)
- Evonik acquires the pharmaceuticals business of SurModics, Inc. http://corporate.evonik.de/en/media/press_releases/Pages/news-details.aspx?newsid=23118 (Accessed 23November2011)
- Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation enter exclusive licensing agreement. www.zosanopharma.com/index.php?option=com_content&task=blogcategory&id=31&Itemid=172 (Accessed 23November2011)
- Presentations on Zosano microprojection technology on Zosano Pharma website. www.zosanopharma.com/index.php?option=com_content&task=blogcategory&id=26&Itemid=169 (Accessed 24November2011)
- Hovione and Bend Research enter into collaboration to advance clients‘ best medicines. www.hovione.com/h_press/press_rel/pr11_hovione_bend.htm (Accessed 23September2011)
- Silence Therapeutics signs collaboration with Mirna Therapeutics to evaluate delivery of novel microRNA therapeutics. http://silence-therapeutics.com/content/newsandevents/stories/2011/Silence%20signs%20collaboration%20with%20miRNA%2024%20October.pdf (Accessed 23November2011)
- Therapeutic platform section on the Silence Therapeutics website. http://silence-therapeutics.com/content/therapeuticplatform/deliverytechnology.htm (Accessed 24November2011)
- Alnylam and GlaxoSmithKline form collaboration on RNAi technology for vaccine production. http://phx.corporate-ir.net/phoenix.zhtml?c=148005&p=irol-newsArticle&ID=1624140&highlight= (Accessed 23November2011)
- FDA approves Combivent Respimat (ipratropium bromide and albuterol sulfate) inhalation spray. www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm274684.htm (Accessed 24November2011)
- Combivent® Respimat® website www.combivent.com/respimat.html (Accessed 24November2011)
- Monthly report for October 2011 from the Committee for Advanced Therapies. www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2011/10/WC500116979.pdf (Accessed 24November2011)
- Section on Glybera on the Amsterdam molecular therapy website. www.amtbiopharma.com/products/glybera/ (Accessed 24November2011)
- Questions and answers document on the refusal of the marketing authorisation of Glybera on the EMA website. www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002145/WC500116926.pdf (Accessed 24November2011)
- Entry on Exparel on Drugs@FDA. www.accessdata.fda.gov/drugsatfda_docs/label/2011/022496s000lbl.pdf (Accessed 24November2011)
- Section on ‘How DepoFoam® Works‘ on the Pacira Pharmaceuticals website. www.pacira.com/depofoam-platform/how-it-works.php (Accessed 24November2011)
- Section on Exparel™ on the Pacira Pharmaceuticals website. www.pacira.com/products/exparel.php (Accessed 24November2011)
- Halozyme Therapeutics announces positive results from enzyme-augmented insulin pump trial. www.halozyme.com/Investors/News-Releases/News-Release-Details/2011/Halozyme-Therapeutics-Announces-Positive-Results-From-Enzyme-Augmented-Insulin-Pump-Trial1127092/default.aspx (Accessed 24November2011)
- Halozyme Therapeutics announces data from two Phase 1 studies of PEGPH20 demonstrating targeting of hyaluronan in tumor stroma. www.halozyme.com/Investors/News-Releases/News-Release-Details/2011/Halozyme-Therapeutics-Announces-Data-From-Two-Phase-1-Studies-of-PEGPH20-Demonstrating-Targeting-of-Hyaluronan-in-Tumor-Strom/default.aspx (Accessed 24November2011)
- Santaris Pharma A/S Phase IIa data of miravirsen shows dose-dependent, prolonged viral reduction of 2–3 logs HCV RNA after four-week treatment in Hepatitis C patients. www.santaris.com/news/2011/11/05/santaris-pharma-phase-2a-data-miravirsen-shows-dose-dependent-prolonged-viral-reduct (Accessed 24November2011)
- Section on LNA drug platform on the Santaris Pharma website. www.santaris.com/science/lna-drug-platform (Accessed 24November2011)
- Sunovion‘s investigational ciclesonide nasal aerosol in an HFA propellant, Demonstrated positive results in patients with perennial allergic rhinitis. www.sunovion.com/news/pressReleases/20111105.pdf (Accessed 24November2011)
- Incept LLC website. www.inceptllc.com (Accessed 24November2011)
- Incept LLC and Confluent Surgical (A). Case study by Bhaskar Chakravorti, Toby Stuart, James Weber. Harvard Business School (5 March 2009). http://hbr.org/product/incept-llc-and-confluent-surgical-a/an/809062-PDF-ENG (Accessed 24November2011)
- Dicerna Pharmaceuticals awarded notice of allowance by US patent and trademark office for patent claims broadly covering dicer substrate siRNA molecules. www.dicerna.com/pdf/Dicerna_Patent_PR_Final%2011.1.11.pdf (Accessed 24November2011)